Positive News Sentiment NASDAQ:SLN Silence Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $12.00 +0.15 (+1.27%) (As of 07/1/2022 03:58 PM ET) Add Compare Share Today's Range$10.60▼$12.4450-Day Range$7.99▼$14.2352-Week Range$7.80▼$26.99Volume4,725 shsAverage Volume35,508 shsMarket Capitalization$359.16 millionP/E RatioN/ADividend YieldN/APrice Target$64.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Silence Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside433.3% Upside$64.00 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.24) to ($2.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.94 out of 5 starsMedical Sector579th out of 1,428 stocksPharmaceutical Preparations Industry277th out of 680 stocks 3.5 Analyst's Opinion Consensus RatingSilence Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $64.00, Silence Therapeutics has a forecasted upside of 433.3% from its current price of $12.00.Amount of Analyst CoverageSilence Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.06% of the float of Silence Therapeutics has been sold short.Short Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silence Therapeutics has recently decreased by 8.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLN. Previous Next 3.8 News and Social Media Coverage News SentimentSilence Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Silence Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for SLN on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 6.54% of the stock of Silence Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Silence Therapeutics are expected to grow in the coming year, from ($2.24) to ($2.03) per share.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 30.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Silence Therapeutics (NASDAQ:SLN) StockSilence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.Read More SLN Stock News HeadlinesJune 2, 2022 | finance.yahoo.comSilence Therapeutics to Present at Jefferies Healthcare ConferenceApril 25, 2022 | seekingalpha.comSilence Therapeutics receives $2M in research milestone from Hansoh PharmaJuly 5, 2022 | Vantage Point (Ad)Simple Strategies to Profit in This MarketLearn strategies for how to make money no matter the market direction. Save your seat at our FREE, LIVE online class. Find out how to navigate volatility and choppy markets. April 6, 2022 | finance.yahoo.comSilence Therapeutics to Present at 21st Annual Needham Virtual Healthcare ConferenceApril 3, 2022 | finance.yahoo.comSilence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual MeetingApril 3, 2022 | finance.yahoo.comSilence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)March 24, 2022 | finanznachrichten.deSilence Therapeutics plc: Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501March 17, 2022 | seekingalpha.comSilence Therapeutics plc 2021 Q4 - Results - Earnings Call PresentationJuly 5, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. March 2, 2022 | finance.yahoo.comSilence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022February 21, 2022 | finance.yahoo.comSilence Therapeutics Appoints Craig Tooman President and Chief Executive OfficerFebruary 15, 2022 | finance.yahoo.com8 Medical Stocks to Buy According to Mitchell Blutt’s Consonance CapitalFebruary 9, 2022 | seekingalpha.comSilence Therapeutics' SLN360 for high Lipoprotein(a) shows promise in phase 1 trialFebruary 9, 2022 | finance.yahoo.comSilence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)January 26, 2022 | finance.yahoo.comSilence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and ExpoDecember 12, 2021 | finance.yahoo.comNew Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological DiseasesDecember 1, 2021 | finance.yahoo.comSilence Therapeutics Welcomes Deep Track Capital as New ShareholderNovember 26, 2021 | lse.co.ukSilence Therapeutics to proceed with AIM delisting next weekNovember 5, 2021 | proactiveinvestors.comSilence Therapeutics says US institutional investor buys US$20mln stakeNovember 5, 2021 | finance.yahoo.comSilence Therapeutics Welcomes Frazier Life Sciences as New Key ShareholderOctober 21, 2021 | finance.yahoo.comSilence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D DayOctober 15, 2021 | finance.yahoo.comSilence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ PlatformOctober 15, 2021 | finance.yahoo.comSilence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global MarketOctober 7, 2021 | finance.yahoo.comSilence Therapeutics to Host R&D Day on October 21, 2021September 13, 2021 | finance.yahoo.comSilence Therapeutics (LON:SLN) shareholders have earned a 36% CAGR over the last five yearsSeptember 1, 2021 | finance.yahoo.comSilence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product DevelopmentAugust 25, 2021 | finance.yahoo.comSilence Therapeutics to Participate in September Investor ConferencesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLN CUSIPN/A CIK1479615 Webwww.silence-therapeutics.com Phone44-0-20-3457-6900FaxN/AEmployees105Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/05/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$64.00 High Stock Price Forecast$95.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+433.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.89 Sales & Book Value Annual Sales$17.07 million Price / Sales21.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book30.77Miscellaneous Outstanding Shares29,930,000Free FloatN/AMarket Cap$359.16 million OptionableNot Optionable Beta1.22 Silence Therapeutics Frequently Asked Questions Should I buy or sell Silence Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Silence Therapeutics stock. View analyst ratings for Silence Therapeutics or view top-rated stocks. What is Silence Therapeutics' stock price forecast for 2022? 3 Wall Street research analysts have issued 12-month target prices for Silence Therapeutics' stock. Their SLN stock forecasts range from $33.00 to $95.00. On average, they predict Silence Therapeutics' share price to reach $64.00 in the next twelve months. This suggests a possible upside of 433.3% from the stock's current price. View analysts' price targets for Silence Therapeutics or view top-rated stocks among Wall Street analysts. How has Silence Therapeutics' stock performed in 2022? Silence Therapeutics' stock was trading at $23.89 at the beginning of 2022. Since then, SLN stock has decreased by 49.8% and is now trading at $12.00. View the best growth stocks for 2022 here. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (NASDAQ:SLN) issued its quarterly earnings data on Monday, May, 16th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.27. The company earned $7.68 million during the quarter. View Silence Therapeutics' earnings history. Who are Silence Therapeutics' key executives? Silence Therapeutics' management team includes the following people: Mr. Craig A. Tooman M.B.A., MBA, Pres, CEO & Director (Age 56, Pay $479.16k)Ms. Rhonda L. Hellums, Chief Financial Officer (Age 50, Pay $268.8k)Dr. Giles V. Campion M.D., Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director (Age 68, Pay $614.93k)Ms. Gem Gokmen Hopkins, Head of IR & Corp. CommunicationsDr. Barbara A. Ruskin, Sr. VP, Gen. Counsel & Chief Patent Officer (Age 62)Mr. Eric Fink, Chief HR Officer (Age 44)Dr. John Strafford Ph.D., Sr. VP of Bus. Devel., Alliance Management & New Product Devel.Mr. Jørgen Wittendorff, Sr. VP & Head of ManufacturingDr. Eric Floyd Ph.D., Sr. VP of Regulatory Affairs & Quality Assurance (Age 60)Dr. Marie Wikstrom Lindholm Ph.D., Sr. VP & Head of Molecular Design Who are some of Silence Therapeutics' key competitors? Some companies that are related to Silence Therapeutics include Taro Pharmaceutical Industries (TARO), Zentalis Pharmaceuticals (ZNTL), Sierra Oncology (SRRA), Prothena (PRTA), Agios Pharmaceuticals (AGIO), Madrigal Pharmaceuticals (MDGL), Myovant Sciences (MYOV), Kura Oncology (KURA), 23andMe (ME), Amylyx Pharmaceuticals (AMLX), Prometheus Biosciences (RXDX), Arcutis Biotherapeutics (ARQT), Reata Pharmaceuticals (RETA), IVERIC bio (ISEE) and Syndax Pharmaceuticals (SNDX). View all of SLN's competitors. What is Silence Therapeutics' stock symbol? Silence Therapeutics trades on the NASDAQ under the ticker symbol "SLN." How do I buy shares of Silence Therapeutics? Shares of SLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Silence Therapeutics' stock price today? One share of SLN stock can currently be purchased for approximately $12.00. How much money does Silence Therapeutics make? Silence Therapeutics (NASDAQ:SLN) has a market capitalization of $359.16 million and generates $17.07 million in revenue each year. How many employees does Silence Therapeutics have? Silence Therapeutics employs 105 workers across the globe. How can I contact Silence Therapeutics? Silence Therapeutics' mailing address is 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH. The official website for Silence Therapeutics is www.silence-therapeutics.com. The company can be reached via phone at 44-0-20-3457-6900. This page (NASDAQ:SLN) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
